Literature DB >> 2592508

Simultaneous quantitation of salivary carbamazepine, carbamazepine-10,11-epoxide, phenytoin and phenobarbitone by high-performance liquid chromatography.

G K Herkes1, G E McKinnon, M J Eadie.   

Abstract

A rapid, sensitive and accurate high-performance liquid chromatographic method for the simultaneous quantitation of phenobarbitone, phenytoin, carbamazepine and carbamazepine-10,11-epoxide in saliva is described. Only small volumes of saliva (100 microliters) are required. Separation of the drugs is achieved by reversed-phase chromatography on a Nova-Pak C18 column, with a mobile phase of acetonitrile-phosphate buffer at a flow-rate of 2.0 ml/min. Detection is effected by ultra-violet absorption at 215 nm. The total run time is under 12.5 min per assay. A precipitation but no extraction step is involved, simplifying the assay method. Salivary concentrations in the range 0.25-25 micrograms/ml for carbamazepine, 0.5-20 micrograms/ml for phenytoin and phenobarbitone and 0.4-20 micrograms/ml for carbamazepine-10,11-epoxide can be measured. Recovery varies from 94 to 108%. The method has been used for routine measurements of anticonvulsants in saliva collected daily from patients with intractable epilepsy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2592508     DOI: 10.1016/s0378-4347(00)82561-x

Source DB:  PubMed          Journal:  J Chromatogr


  3 in total

1.  Porcine ear skin as a model for the assessment of transdermal drug delivery to premature neonates.

Authors:  Nabila Sekkat; Yogeshvar N Kalia; Richard H Guy
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

Review 2.  Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants.

Authors:  H Liu; M R Delgado
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

3.  A simple collection method for saliva in children: potential for home monitoring of carbamazepine therapy.

Authors:  K Y Chee; D Lee; D Byron; D Naidoo; A Bye
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.